These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22119310)

  • 1. Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.
    Malerba M; Radaeli A; Morjaria JB
    Drug Discov Today; 2012 May; 17(9-10):496-504. PubMed ID: 22119310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.
    Tashkin DP; Fabbri LM
    Respir Res; 2010 Oct; 11(1):149. PubMed ID: 21034447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM; Beier J
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
    Monaco TJ; Hanania NA
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):285-299. PubMed ID: 28868931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.
    Malerba M; Radaeli A; Montuschi P; Babu KS; Morjaria JB
    Expert Opin Investig Drugs; 2017 Mar; 26(3):319-329. PubMed ID: 28117615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
    Beeh KM; Beier J
    Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the use of indacaterol in patients with COPD.
    Brienza NS; Amor-Carro O; Ramos-Barbón D
    Ther Adv Respir Dis; 2011 Feb; 5(1):29-40. PubMed ID: 21059700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.
    Zafar MA; Droege C; Foertsch M; Panos RJ
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1687-701. PubMed ID: 25139313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel controllers of airway obstruction in COPD patients].
    Płusa T
    Pol Merkur Lekarski; 2011 Jan; 30(175):5-9. PubMed ID: 21542237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?
    Reddy CB; Kanner RE
    Drugs Aging; 2007; 24(8):615-28. PubMed ID: 17702532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
    Tashkin DP
    Expert Opin Pharmacother; 2010 Aug; 11(12):2077-85. PubMed ID: 20642373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indacaterol. A long-acting beta-2 agonist, no advantages in COPD.
    Prescrire Int; 2011 Sep; 20(119):201-5. PubMed ID: 21954512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
    Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
    J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
    Bateman ED; Rabe KF; Calverley PM; Goehring UM; Brose M; Bredenbröker D; Fabbri LM
    Eur Respir J; 2011 Sep; 38(3):553-60. PubMed ID: 21737553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
    Xia N; Wang H; Nie X
    PLoS One; 2015; 10(9):e0137904. PubMed ID: 26378450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.